












GLP-1s in the pipeline

A strong product pipeline is anticipated to propel the growth of the GLP-1 agonist market.

Additional innovative products in terms of formulations, improved bioavailability, combination therapies, and route of administration are being developed. Staying vigilant in monitoring this robust pipeline is critical to helping proactively manage this complex class of drugs by helping to ensure clinical impact while minimizing cost.

	Drug	Dosage	Manufacturer	Type 2 Diabetes	Obesity
PHASE 3	CagriSema (cagrilintide/semaglutide)*		Novo Nordisk	X	X
	IcoSema (insulin icodec/semaglutide)*		Novo Nordisk	X	
	orforglipron		Eli Lilly	X	X
	retatrutide		Eli Lilly		X
	semaglutide		Novo Nordisk	FDA approved 9/20/2019 (Rybelsus)	X†
	tirzepatide		Eli Lilly	FDA approved 5/13/2022 (Mounjaro)	X†
PHASE 2	AMG133		Amgen		X
	danuglipron		Pfizer	X	X
	pemvidutide		Altimune		X
	retatrutide		Eli Lilly	X	
	survodutide		Boehringer Ingelheim/ Zealand Pharma	X	X

In addition, GLP-1 manufacturers are seeking approval for supplemental indications including treatment of non-alcoholic steatohepatitis (NASH), obstructive sleep apnea, risk reduction for major adverse cardiovascular events, and peripheral arterial disease.

Many of these are likely to be approved or launched within the next two years.

CVS Pipeline Services anticipates that the financial impact of most is replacement spend within the pharmacy benefit, with the exception of Ozempic for NASH, which has received Breakthrough Therapy designation and would likely result in incremental spend.

* New combination of existing GLP-1 agonist.

† New formulation of existing GLP-1 agonist.

The information contained herein is compiled from independent clinical sources and is provided for informational purposes only. Due to circumstances beyond CVS Health's control, prospective drug launch dates are subject to change without notice. This information should not be solely relied upon for decision-making purposes. This document includes products that may fall under a general specialty or non-specialty drug benefit. All products contained herein may not be provided by CVS Specialty Pharmacy.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health. CVS Health Pipeline Services.

©2023 CVS Health and/or one of its affiliates. All rights reserved. 101223 (W)

